ClosedPublished 6 Nov 2026
Acrivon Therapeutics, Inc. /
Aqilion AB
Acrivon Therapeutics expands into immunology with Aqilion programs
- Terms
- Not stated
- Stage
- Closed
01 / BuyerAcrivon Therapeutics, Inc.
02 / TargetAqilion AB
What happened
Acrivon Therapeutics, Inc. acquired programs from Aqilion AB, including an oral JAK1 inhibitor and a preclinical PKCθ inhibitor program, establishing immunology and inflammation as a strategic pillar alongside oncology.
The transaction closed concurrently with the signing of the definitive agreement for undisclosed cash consideration, with no future royalties or milestone obligations.
Who bought Aqilion AB?
Acrivon Therapeutics, Inc. acquired Aqilion AB (Closed, published 6 Nov 2026).
The source
01
Source
Acrivon Therapeutics expands into immunology with Aqilion programs
Original filingUnlock with ProTimeline
Published by the source
Deal Web
Every firm and person on this deal, and how they connect. Open any name to see their other deals.
This dealAcrivon Therapeutics, Inc. / Aqilion ABClosed · Published 6 Nov 2026
BuyerAcrivon Therapeutics, Inc.This dealAcrivon Therapeutics, Inc. / Aqilion AB
Closed · Acrivon Therapeutics, Inc. acquired Aqilion AB (Closed, published 6 Nov 2026).
Published 6 Nov 2026Timeline
Hover or tap a name to see how it connects, and when- Published by the source
Deal Web as a list
- Acrivon Therapeutics, Inc. (Buyer) acquired this deal. Acrivon Therapeutics, Inc.: 1 deal on Carrywatch.
By email · Weekly